Quest Diagnostics Incorporated (DGX)
NYSE: DGX · Real-Time Price · USD
166.45
-0.46 (-0.28%)
At close: Jul 21, 2025, 4:00 PM
167.50
+1.05 (0.63%)
After-hours: Jul 21, 2025, 5:02 PM EDT
Quest Diagnostics Revenue
Quest Diagnostics had revenue of $2.65B in the quarter ending March 31, 2025, with 12.09% growth. This brings the company's revenue in the last twelve months to $10.16B, up 9.38% year-over-year. In the year 2024, Quest Diagnostics had annual revenue of $9.87B with 6.70% growth.
Revenue (ttm)
$10.16B
Revenue Growth
+9.38%
P/S Ratio
1.82
Revenue / Employee
$181,393
Employees
56,000
Market Cap
18.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.87B | 620.00M | 6.70% |
| Dec 31, 2023 | 9.25B | -631.00M | -6.38% |
| Dec 31, 2022 | 9.88B | -905.00M | -8.39% |
| Dec 31, 2021 | 10.79B | 1.35B | 14.32% |
| Dec 31, 2020 | 9.44B | 1.71B | 22.15% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
DGX News
- 6 days ago - Quest Diagnostics Introduces Testing for Oropouche Virus - PRNewsWire
- 6 days ago - Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today - Seeking Alpha
- 12 days ago - Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease - PRNewsWire
- 26 days ago - Quest Diagnostics Releases 2024 Corporate Responsibility Report - PRNewsWire
- 4 weeks ago - Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025 - PRNewsWire
- 5 weeks ago - Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology - PRNewsWire
- 2 months ago - More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals - PRNewsWire
- 2 months ago - Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference - PRNewsWire